Trials of Zika vaccine are set to begin in North AmericaBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i3588 (Published 28 June 2016) Cite this as: BMJ 2016;353:i3588
- Owen Dyer
The first potential vaccine against the Zika virus to be approved for testing in humans is set to begin phase I clinical trials in the United States.
The vaccine’s maker, Inovio, of Pennsylvania, is currently completing the paperwork to begin recruitment of 40 volunteers to participate in Philadelphia, Miami, and an undisclosed site in Canada.
The first vaccinations are expected within a few weeks, said Inovio’s president, Joseph Kim, and the first results by the year’s end. In animal trials the experimental vaccine, known as GLS-5700, elicited an immune response in mice, rabbits, and monkeys.
Other collaborators in the project include the University of Pennsylvania, the biomedical Wistar Institute in Philadelphia, and GeneOne Life Science, of …